

**Financial results for the year
ended March 31, 2010**

< Supplement >

May 10, 2010

 **SHIONOGI & CO., LTD.**

Contents

- 1 Financial results and forecast <Consolidated/Non-consolidated>
- 2 Sales by Segment
- 3 Management index (Consolidated)
- 4 Financial results of significant consolidated subsidiaries
- 5 Capital investments and depreciation cost
- 6 R&D expenses
- 7 Employees
- 8 Consolidated statement of income
- 9 Consolidated balance sheets
- 10 Quarterly trend for FY2008 and FY2009
- 11 Consolidated affiliated companies and affiliated company accounted for by the equity method
- 12 Main Events during Fiscal 2009
- 13 Pipeline (as of May 2010)

1. Financial results and forecast <Consolidated/Non-consolidated>

< Consolidated >

(Units: 100 million yen)

	FY2008 Results	FY2009 Results	FY2010 Forecast	Change		FY2010 1H Forecast
				FY2009	FY2010	
Net Sales	2,275	2,785	2,950	510	165	1,460
<i>change %</i>	(6.2)	(22.4)	(5.9)			(10.1)
Operating Income	320	524	610	204	86	230
<i>change %</i>	(Δ 20.8)	(63.8)	(16.3)			(28.9)
Ordinary Income	320	505	590	185	85	220
<i>change %</i>	(Δ 19.7)	(57.9)	(16.8)			(34.2)
Net Income	156	386	390	230	4	145
<i>change %</i>	(Δ 37.5)	(146.6)	(1.0)			(25.1)

Note: Change % shows changes from the same period of the previous fiscal year

Because of changing fiscal term, FY 2010, Budgets of subsidiaries in the United States are 15 months from January 2010 to March 2011.

< Non-consolidated >

(Units: 100 million yen)

	FY2008 Results	FY2009 Results	FY2010 Forecast	Change		FY2010 1H Forecast
				FY2009	FY2010	
Net Sales	2,067	2,285	2,390	218	105	1,140
<i>change %</i>	(2.9)	(10.6)	(4.6)			(5.2)
Operating Income	362	492	570	130	78	230
<i>change %</i>	(Δ 0.4)	(35.9)	(15.7)			(36.3)
Ordinary Income	379	499	565	120	66	230
<i>change %</i>	(1.8)	(31.7)	(13.1)			(36.6)
Net Income	238	407	380	169	Δ 27	155
<i>change %</i>	(6.2)	(70.8)	(Δ 6.8)			(32.5)

Note: Change % shows changes from the same period of the previous fiscal year

Because of changing fiscal term, FY 2010, Budgets of subsidiaries in the United States are 15 months from January 2010 to March 2011.

2.Sales by Segment

(Units: 100 million yen)

	FY2008 Results	FY2009 Results	FY2010 Forecast	Change		FY2010 1H Forecast
				FY2009	FY2010	
Pharmaceuticals and related business	2,230	2,744	2,920	514	176	1,450
<i>change %</i>	(7.0)	(23.0)	(6.4)			(11.1)
Ethical drugs	1,532	1,525	1,536	△ 7	11	739
<i>change %</i>	(△ 1.2)	(△ 0.5)	(0.7)			(△ 1.1)
CRESTOR	177	242	300	65	58	145
FLOMOX	273	240	190	△ 33	△ 50	90
RINDERON	96	95	89	△ 1	△ 6	48
CLARITIN	96	90	81	△ 6	△ 9	34
FLUMARIN	101	87	66	△ 14	△ 21	36
OXYCONTIN	77	85	95	8	10	47
VANCOMYCIN	81	61	39	△ 20	△ 22	22
IMUNACE	61	46	37	△ 15	△ 9	20
IRBETAN	12	38	83	26	45	38
FINIBAX	29	34	43	5	9	21
DIFFERIN	12	22	39	10	17	19
PIRESPA	2	15	34	13	19	14
AVELOX	15	10	3	△ 5	△ 7	3
RAPIACTA	-	6	40	6	34	5
CYMBALTA	-	-	10	-	10	5
Export/Overseas operations	186	491	616	305	125	340
<i>change %</i>	(196.2)	(163.5)	(25.5)			(42.4)
Shionogi Pharma, Inc.	92	386	513	294	127	297
DORIPENEM	35	52	54	17	2	18
Contract manufacturing	57	74	25	17	△ 49	9
<i>change %</i>	(△ 2.2)	(28.8)	(△ 66.3)			(△ 73.8)
OTC and quasi-drugs	52	54	55	2	1	29
<i>change %</i>	(△ 7.1)	(3.2)	(1.1)			(△ 1.9)
SEDES	23	24	24	1	0	12
POPON-S	10	11	11	1	0	6
Diagnostics	33	29	28	△ 4	△ 1	13
<i>change %</i>	(△ 2.2)	(△ 11.2)	(△ 4.9)			(△ 16.8)
Royalty income	368	570	660	202	90	320
<i>change %</i>	(15.1)	(54.6)	(15.8)			(33.3)
CRESTOR	343	500	635	157	135	305
Other business	44	41	30	△ 3	△ 11	10
<i>change %</i>	(△ 24.1)	(△ 8.2)	(△ 26.2)			(△ 52.3)
Total	2,275	2,785	2,950	510	165	1,460
<i>change %</i>	(6.2)	(22.4)	(5.9)			(10.1)

Note: Change % shows changes from the same period of the previous fiscal year

Sales of each product are shown on non-consolidated basis

Because of changing fiscal term, FY 2010, Budgets of subsidiaries in the United States are 15 months from January 2010 to March 2011.

3. Management index <Consolidated>

(Management index trend <Consolidated>)

		FY2007	FY2008	FY2009
Ratio of operating income to net sales	%	18.9	14.1	18.8
Ratio of ordinary income to net sales	%	18.6	14.1	18.1
Ratio of net income to net sales	%	11.7	6.9	13.9
Total asset turnover		0.51	0.50	0.53
Equity ratio	%	82.7	61.7	63.2
Return on asset (ROA)	%	9.5	7.0	9.7
Return on equity (ROE)	%	7.3	4.8	11.9
Dividend payout ratio	%	29.6	59.9	31.2
Earnings per share	yen	74.21	46.75	115.33

4. Financial results of significant consolidated subsidiaries <Shionogi Pharma, Inc.>

< Consolidated statement of income (Summary)>

(Units: million dollar)

	FY2008 Results	FY2009 Results	FY2010 forecast	FY2009 1H Results	FY2010 1H Forecast
Net sales	101	413	570	192	330
Cost of sales	13	52	66	19	42
SG & A expenses	58	293	394	149	233
Operating income	28	67	110	23	55
Amortization of intangible assets (Sales right)	9	34	45	16	27
Amortization of goodwill	9	39	49	19	29

(Units: 100 million yen)

	FY2008 Results	FY2009 Results	FY2010 forecast	FY2009 1H Results	FY2010 1H Forecast
Net sales	92	386	513	183	297
Cost of sales	12	48	58	18	37
SG & A expenses	53	274	355	142	210
Operating income	26	63	100	22	50
Amortization of intangible assets (Sales right)	8	32	40	16	24
Amortization of goodwill	9	37	44	19	26

Note: Because of changing fiscal term, FY 2010, Budgets of subsidiaries in the United States are 15 months from January 2010 to March 2011.

5. Capital investments and depreciation cost

(Units: 100 million yen)

	FY2008 Results	FY2009 Results	FY2010 Forecast	Change		FY2010 1H Forecast
				FY2009	FY2010	
<Consolidated>						
Investment in equipments	108	125	180	17	55	100
Depreciation cost	134	179	195	45	16	106
Amortization of goodwill	9	37	44	28	7	26
<Non-consolidated>						
Investment in equipments	93	103	170	10	67	95
Depreciation cost	108	104	105	△ 4	1	53

Note: Because of changing fiscal term, FY 2010, Budgets of subsidiaries in the United States are 15 months from January 2010 to March 2011.

6. R&D expenses

(Units: 100 million yen)

	FY2008 Results	FY2009 Results	FY2010 Forecast	Change		FY2010 1H Forecast
				FY2009	FY2010	
<Consolidated>						
R&D expenses	528	518	543	△ 10	25	295
<i>change %</i>	(31.1%)	(△1.9%)	(4.8%)			(5.7%)
In-process R&D expenses	96	—	—	△96	—	—
% to net sales	23.2	18.6	18.4			20.2
<Non-consolidated>						
R&D expenses	422	467	480	45	13	250
<i>change %</i>	(5.0%)	(10.7%)	(2.6%)			(△3.2%)
% to net sales	20.4	20.5	20.1			21.9

Note: Change % shows changes from the same period of the previous fiscal year

Because of changing fiscal term, FY 2010, Budgets of subsidiaries in the United States are 15 months from January 2010 to March 2011.

7. Employees

	FY2008 Results	FY2009 Results	FY2010 Forecast	Change		FY2010 1H Forecast
				FY2009	FY2010	
Consolidated	6,010	5,887	5,650	△ 123	△ 237	5,690
Non-consolidated	4,262	4,124	4,140	△ 138	16	4,180

8. Consolidated statement of income

(Unites: Million yen)

	FY2008 Results	FY2009 Results	Change	
Net sales	227,511	278,502	50,991	Royalty income: +20.2 billion yen Export-use doripenem: +1.7 billion yen Net sales of Shionogi Pharma: +29.4 billion yen
Cost of sales	70,928	76,263	5,335	
Gross profit	156,582	202,239	45,657	Shionogi R&D expenses: +4.5 billion yen Shionogi Pharma SG&A expenses: 27.4 billion yen Amortization of intangible assets and goodwill: 6.9 billion yen
Selling, general and administrative expenses	124,568	149,801	25,233	
Operating income	32,014	52,438	20,424	
Non-operating income	3,343	2,579	△ 764	
Interest income	1,072	484	△ 588	Decrease in interest income: Decrease in resouses used accompanied with acquisition of Shionogi Pharma
Dividends income	1,263	1,124	△ 139	
Royalty income	426	—	△ 426	
Other	581	970	389	
Non-operating expenses	3,354	4,494	1,140	
Interest expenses	701	1,675	974	Increase in interest expenses: - Increase in loans: 771 million yen - Increase in straight bonds issued: 242 million yen
Contribution	1,248	1,412	164	
Loss on disposal of inventories	426	251	△ 175	
Other	977	1,155	178	
Ordinary income	32,003	50,522	18,519	
Extraordinary income	213	10,251	10,038	
Gain on transfer of business	—	5,351	5,351	Divesting of Bushu Pharmaceuticals Ltd.
Gain on exchange from business combination	—	4,900	4,900	Gain on exchange of investment securities of Omwell Incorporated
Gain on sales of investment securities	213	—	△ 213	
Extraordinary loss	1,430	2,233	803	
Loss on valuation of investment securities	—	1,942	1,942	Loss on valuation of Enanta share value because of terminating S-013420
Impairment loss	—	199	199	Effect of discontinue sales of AVELOX
Special contract expenses	700	—	△ 700	
Special retirement expenses	362	—	△ 362	
Loss on disaster	253	—	△ 253	
Loss on valuation of inventories	89	—	△ 89	
Loss on sales of investment securities	25	—	△ 25	
Other	—	90	90	
Income before income taxes and minority interests	30,785	58,540	27,755	
Income taxes-current	14,717	21,145	6,428	
Income taxes-deferred	369	△ 1,246	△ 1,615	
Minority interests in income	37	15	△ 22	
Net income	15,661	38,625	22,964	

9-1. Consolidated balance sheets (Assets)

(Unites: Million yen)

	As of Mar. 31 2009	As of Mar. 31 2010	Change	
(Assets)				
Current assets				
Cash and deposits	23,349	33,532	10,183	
Notes and accounts receivable-trade	75,380	79,414	4,034	
Short-term investment securities	35,453	70,677	35,224	Increase in negotiable certificate of deposit: 35.9 billion yen
Merchandise and finished goods	20,632	26,931	6,299	
Work in process	12,556	14,058	1,502	
Raw materials and supplies	9,838	8,350	△ 1,488	
Other	25,525	17,710	△ 7,815	
Allowance for doubtful accounts	△ 12	△ 11	1	
Total current assets	202,724	250,664	47,940	
Noncurrent assets				
Property, plant and equipment	71,811	62,447	△ 9,364	Divesting of Bushu Pharmaceuticals Ltd. 11.5 billion yen
Intangible assets				
Goodwill	71,625	69,874	△ 1,751	
Other	48,763	49,190	427	
Total Intangible assets	120,388	119,065	△ 1,323	
Investments and other assets				
Investment securities	66,813	71,870	5,057	
Other	40,236	36,835	△ 3,401	Decrease of prepaid pension expenses: 1.56 billion yen
Allowance for doubtful accounts	△ 121	△ 121	-	
Total investments and other assets	106,928	108,584	1,656	
Total noncurrent assets	299,128	290,097	△ 9,031	
Total assets	501,852	540,761	38,909	

9-2. Consolidated balance sheets (Liabilities/Net Assets)

(Unites: Million yen)

	As of Mar. 31 2009	As of Mar. 31 2010	Change
(Liabilities)			
Current liabilities			
Notes and accounts payable-trade	15,444	13,400	△ 2,044
Short-term loans payable	10,000	—	△ 10,000
Current portion of long-term loans payable	14,000	14,000	—
Income taxes payable	8,131	13,479	5,348
Provision for bonuses	5,325	6,473	1,148
Other provision	2,336	1,316	△ 1,020
Other	21,566	18,159	△ 3,407
Total Current liabilities	76,804	66,829	△ 9,975
Noncurrent liabilities			
Bonds payable	—	30,000	30,000
Long-term loans payable	91,000	77,000	△ 14,000
Provision for retirement benefits	7,793	8,077	284
Other provision	155	—	△ 155
Other	16,005	16,878	873
Total noncurrent liabilities	114,954	131,955	17,001
Total liabilities	191,759	198,785	7,026
(Net Assets)			
Shareholders' equity			
Capital stock	21,279	21,279	—
Capital surplus	20,227	20,227	—
Retained earnings	304,761	332,669	27,908
Treasury stock	△ 19,652	△ 19,733	△ 81
Total shareholders' equity	326,616	354,443	27,827
Valuation and translation adjustments			
Valuation difference on available-for-sale securities	8,207	10,362	2,155
Foreign currency translation adjustment	△ 25,188	△ 23,301	1,887
Total valuation and translation adjustments	△ 16,980	△ 12,939	4,041
Minority interests	458	471	13
Total net assets	310,093	341,976	31,883
Total liabilities and net assets	501,852	540,761	38,909

Repayment of bridge loan

Issuance of straight bonds

Repayment of syndicate loan 13
billion yen

10-1 Quarterly trend for FY2008 and FY2009 (Sales by Segment)

(Units: 100 million yen)

FY2008	FY2008 1Q actual	Y on Y change %	FY2008 2Q actual	Y on Y change %	FY2008 3Q actual	Y on Y change %	FY2008 4Q actual	Y on Y change %
Pharmaceuticals and related business	511	2.9	526	4.8	587	2.2	606	18.7
Ethical drugs	380	0.5	362	△ 0.3	423	△ 4.1	367	△ 0.5
CRESTOR	38	99.9	46	79.7	48	55.0	45	56.1
FLOMOX	61	△ 5.8	60	1.9	88	△ 4.4	64	△ 9.4
RINDERON	26	△ 2.4	26	△ 3.2	25	△ 6.7	20	△ 4.0
FLUMARIN	25	△ 17.3	30	△ 10.8	27	△ 19.6	19	△ 21.7
OXYCONTIN	20	27.7	19	22.3	24	12.3	14	2.1
CLARITIN	18	6.4	15	25.1	20	32.6	44	△ 5.7
VANCOMYCIN	23	△ 22.2	23	△ 10.3	18	△ 39.4	17	△ 17.8
IMUNACE	20	△ 35.4	16	△ 52.2	12	△ 53.3	13	△ 51.8
FINIBAX	6	16.5	7	10.1	9	15.7	7	17.7
IRBETAN	8	-	2	-	1	-	1	-
DIFFERIN	-	-	-	-	7	-	5	-
PIRESPA	-	-	-	-	0.4	-	1	-
AVELOX	4	14.2	2	△ 40.9	5	△ 21.5	3	△ 20.7
Export/Overseas operations	19	25.4	22	53.3	28	104.1	117	502.3
Shionogi Pharma, Inc.	-	-	-	-	-	-	92	-
DORIPENEM	5	-	6	528.6	15	-	9	246.5
Contract manufacturing	12	22.5	18	8.6	16	△ 14.1	12	△ 16.9
OTC and quasi-drugs	14	△ 2.6	14	△ 1.4	14	△ 11.9	10	△ 13.3
SEDES	6	△ 2.5	6	3.2	6	△ 15.8	4	△ 14.5
POPON-S	3	3.5	3	△ 12.0	3	4.1	2	△ 9.7
Diagnostics	9	0.6	8	△ 1.2	8	△ 6.0	8	△ 2.1
Royalty income	75	9.5	102	19.3	98	27.7	93	4.6
CRESTOR	72	8.3	93	20.6	93	26.6	84	4.5
Other business	6	14.5	7	△ 80.8	11	37.6	20	160.5
Total	517	3.0	533	△ 1.1	598	2.7	626	20.8

FY2009	FY2009 1Q actual	Y on Y change %	FY2009 2Q actual	Y on Y change %	FY2009 3Q actual	Y on Y change %	FY2009 4Q actual	Y on Y change %
Pharmaceuticals and related business	634	24.2	671	27.5	728	23.9	711	17.3
Ethical drugs	372	△ 2.2	375	3.5	424	0.3	354	△ 3.4
CRESTOR	55	44.1	60	33.2	69	43.6	58	26.3
FLOMOX	58	△ 4.6	55	△ 9.1	79	△ 10.2	48	△ 24.6
RINDERON	26	△ 1.2	25	0.2	23	△ 5.3	21	1.9
CLARITIN	18	1.1	16	8.0	20	2.2	36	△ 18.3
FLUMARIN	22	△ 12.9	25	△ 14.7	23	△ 16.6	17	△ 10.2
OXYCONTIN	22	6.5	20	6.0	25	6.5	18	30.4
VANCOMYCIN	17	△ 26.3	17	△ 24.2	15	△ 18.1	12	△ 28.8
IMUNACE	13	△ 34.3	13	△ 21.3	11	△ 8.9	9	△ 29.1
IRBETAN	4	△ 53.5	8	359.7	12	-	14	919.3
FINIBAX	8	35.0	10	26.2	8	△ 6.5	8	14.4
DIFFERIN	5	-	5	-	6	△ 6.0	6	5.1
PIRESPA	3	-	3	-	4	-	5	280.8
AVELOX	3	△ 26.7	2	△ 10.4	3	△ 42.8	2	△ 37.0
RAPIACTA	-	-	-	-	-	-	6	-
Export/Overseas operations	119	521.0	120	447.6	127	346.7	125	7.1
Shionogi Pharma, Inc.	95	-	88	-	99	-	104	12.2
DORIPENEM	12	157.5	17	189.2	13	△ 18.8	10	16.7
Contract manufacturing	14	22.8	20	6.9	19	20.5	21	79.6
OTC and quasi-drugs	14	△ 0.8	16	8.8	14	△ 3.2	10	10.1
SEDES	6	5.7	8	12.0	6	△ 0.1	4	8.0
POPON-S	2	△ 6.4	4	30.4	3	△ 4.0	2	1.4
Diagnostics	8	△ 10.7	8	△ 4.7	6	△ 23.3	7	△ 5.7
Royalty income	105	39.4	135	31.8	138	40.8	192	106.6
CRESTOR	100	38.2	125	34.4	132	41.5	143	69.4
Other business	5	△ 9.1	16	114.2	10	△ 5.0	10	△ 53.4
Total	640	23.8	686	28.6	738	23.4	721	15.0

Sales of each product are shown on non-consolidated basis

10-2 Quarterly trend for FY2008 and FY2009 (Consolidated statements of income)

(Units: 100 million yen)

FY2008	FY2008 1Q Actual	Y on Y change %	FY2008 2Q Actual	Y on Y change %	FY2008 3Q Actual	Y on Y change %	FY2008 4Q Actual	Y on Y change %
Net sales	517	3.0	533	Δ 1.1	598	2.7	626	20.8
Cost of sales	32.0 165	2.6	30.8 164	Δ 11.5	32.1 191	4.8	30.0 187	20.3
Gross profit	351	3.2	368	4.3	406	1.7	438	21.0
SG & A expenses	52.4 271	3.8	49.7 265	1.1	60.4 361	31.6	55.6 348	36.6
Selling & general expenses	166	1.4	162	Δ 1.0	170	4.7	218	37.2
R & D expenses	104	7.8	102	4.5	190	71.0	129	35.7
Operating income	15.6 80	1.1	19.5 103	13.4	7.5 44	Δ 64.0	14.5 90	Δ 15.9
Non-operating income & expenses	2		2		0		Δ 4	
Ordinary income	16.2 83	Δ 2.1	19.9 105	23.2	7.4 44	Δ 64.3	13.7 85	Δ 16.5
Extraordinary income & loss	0		0		0		Δ 10	
Income before income taxes and minority interests	82		106		43		75	
Income taxes and minority interests	29		41		53		27	
Net income	10.4 53	0.3	12.1 64	19.1	- Δ 9	-	7.7 48	Δ 24.6

FY2009	FY2009 1Q Actual	Y on Y change %	FY2009 2Q Actual	Y on Y change %	FY2009 3Q Actual	Y on Y change %	FY2009 4Q Actual	Y on Y change %
Net sales	640	23.8	686	28.6	738	23.4	720	15.0
Cost of sales	26.9 172	4.1	28.7 196	19.5	27.5 202	5.7	26.6 191	1.9
Gross profit	468	33.1	489	32.7	535	31.8	529	20.6
SG & A expenses	63.6 407	50.3	54.2 372	40.3	49.3 363	0.6	49.3 355	2.0
Selling & general expenses	246	48.4	254	56.5	238	39.4	241	10.6
R & D expenses	161	53.4	118	14.8	125	Δ 34.2	113	Δ 12.5
Operating income	9.5 60	Δ 24.8	17.1 118	13.3	23.3 171	282.4	24.2 174	92.3
Non-operating income & expenses	Δ 2		Δ 12		Δ 1		Δ 2	
Ordinary income	9.1 58	Δ 30.3	15.4 105	Δ 0.3	23.0 169	282.8	23.8 171	99.3
Extraordinary income & loss	Δ 1		1		48		31	
Income before income taxes and minority interests	57		106		218		203	
Income taxes and minority interests	10		Δ 37		Δ 79		Δ 72	
Net income	7.2 46	Δ 14.6	10.2 69	8.4	18.9 139	-	18.2 130	172.2

11. Consolidated affiliated companies and affiliated company accounted for by the equity method

<Consolidated affiliated companies>

No.	Company name	Location	Common stock	Business status	Establish	Closing date	Ownership (%)
1	Nichia Pharmaceutical Industries Ltd.	Tokushima, Japan	JPY 200 million	Mfg. of pharmaceutical raw materials	August 24, 1976	March 31	75
2	Saishin Igaku Co., Ltd.	Osaka, Japan	JPY 90 million	Publication of medical information	December 21, 1998	March 31	100
3	Shionogi Engineering Service Co., Ltd.	Hyogo, Japan	JPY 20 million	Inspection and maintenance of pharmaceuticals mfg. equipment	November 2, 1992	March 31	100
4	Shionogi General Service Co., Ltd.	Osaka, Japan	JPY 10 million	Traveling, Insurance agency	November 2, 1992	March 31	100
5	Shionogi Analysis Center Co., Ltd.	Hyogo, Japan	JPY 200 million	Contract testing and analysis on medicine	December 21, 2007	March 31	100
6	Aburahi AgroResearch Co., Ltd.	Shiga, Japan	JPY 10 million	Contract Laboratories for Agro Chemicals	February 26, 2004	March 31	* 100
7	Taiwan Shionogi & Co., Ltd.	Taipei, Taiwan, R.O.C.	TW\$ 92 million	Mfg. and sale of pharmaceuticals	December 26, 1963	December 31	100
8	Shionogi USA Holding, Inc.	Delaware, U.S.A.	US\$ 6	Holding company	August 25, 2008	December 31	100
9	Shionogi USA, Inc.	Delaware, U.S.A.	US\$ 10 million	Contract research and sale for pharmaceuticals	February 15, 2001	December 31	100
10	SG Holding, Inc.	Delaware, U.S.A.	US\$ 140	Holding company	September 27, 2001	December 31	100
11	Shionogi Pharma, Inc.	Georgia, U.S.A.	US\$ 0.01	Mfg. and sale of pharmaceuticals	July 9, 1992	December 31	* 100
12	Ezose Sciences, Inc.	Delaware, U.S.A.	US\$ 9	Serum glycan analysis contract services	March 3, 2009	December 31	* 86.66

<Affiliated company accounted for by the equity method>

No.	Company name	Location	Common stock	Business status	Establish	Closing date	Ownership (%)
1	Shionogi-GlaxoSmithKline Holding L.P.	Cayman Islands	-	Holding company	October 19, 2001	December 31	* 50

* Incl. Indirect ownership

Note: Five consolidated affiliated companies are not shown on this table as the scale of their business is very small.

12. Main events during fiscal 2009

【 Shionogi Co., Ltd.】

- Issuance of Unsecured Straight Bonds(30 billion yen)
- Reduction of the minimum investment unit (from 1,000 shares to 100 shares)
- Newly-marketed OTC and quasi-drugs, Popon[®] B Fresh, etc.
- Agreement with United Kingdom on International Industry-Academic Collaboration Initiatives
- Launched Rapiacta[®] Bag and Vial for Intravenous Drip Infusion, a novel for anti-viral Drug for Influenza
- Subsidiary, Bushu Pharmaceuticals Ltd., transfer
- Launched Cymbalta[®] Capsules, a antidepressant drug

【 Shionogi Pharma, Inc. 】

- Acquisition of global rights for PSD 502, a treatment of premature ejaculation
- Launched Ulesfia[™] lotion, a head lice treatment
- NDA submission to the FDA for Glycopyrrolate, a treatment for chronic
- The sNDA submission to the FDA for Clonixel to treat ADHD
- Acquire Adrenex Pharmaceuticals, Inc., a U.S. Specialty Phamaceutial Company
- Launched Adrenaclick, for the emergency treatment of anaphylaxis
- Agreement with QuantRx Pharmaceuticals to market Ospemifene

13. Pipeline (as of May 2010)

<In Japan>

Code No. (Generic name)	Category (Administration)	Indication	Stage	Origin	Development
LY248686 (Duloxetine hydrochloride)	SNRI (serotonin & noradrenaline reuptake inhibitor) (Oral)	Depression	Launch (April 2010)	Eli Lilly and Company (USA)	In-house
LY248686 (Duloxetine hydrochloride)	SNRI (serotonin & noradrenaline reuptake inhibitor) (Oral)	Diabetic peripheral neuropathic pain	NDA submission (September 2009)	Eli Lilly and Company (USA)	Co-development: Eli Lilly Japan K.K.
S-021812 (Peramivir)	Neuraminidase inhibitor (Injection)	Pediatric influenza infection	NDA submission (February 2010)	BioCryst Pharmaceuticals, Inc. (USA)	In-house
S-4661 (Doripenem hydrate)	Carbapenem antibiotic (Injection)	Addition of new dosage regimen (1g t.i.d. for serious infection)	NDA submission (March 2010)	In-house	In-house
S-4661 (Doripenem hydrate)	Carbapenem antibiotic (Injection)	Pediatric infection	Phase III	In-house	In-house
S-811717 (Oxycodone hydrochloride)	Natural opium alkaloids (Injection)	For the treatment of moderate to severe pain in patients with cancer pain	Phase III	Napp Pharmaceutical Limited (UK)	In-house
S-474474 (Irbesartan/trichlormethiazide)	Angiotensin receptor blocker/diuretic combination (Oral)	Hypertension	Phase III	Irbesartan: Sanofi Aventis & Trichlormethiazide: Shionogi	In-house
S-555739	Prostaglandin D2 receptor antagonist (Oral)	Allergic disease	Phase IIa	In-house	In-house
S-2367 (Velneperit)	Neuropeptide Y Y5 receptor antagonist (Oral)	Obesity	Phase II	In-house	In-house
S-444823	Cannabinoid receptor agonist (Topical)	Atopic dermatitis	Phase IIa	In-house	In-house
S-288310	Peptide cancer vaccine (injection)	Bladder cancer	Phase I/II	OncoTherapy Science, Inc. (Japan)	In-house
S-888711	Small molecule TPO mimetic (Oral)	Thrombocytopenia	Phase I	In-house	In-house
S-297995	Peripheral opioid receptor antagonist (Oral)	Alleviation of opioid-induced adverse effect	Phase I	In-house	In-house

<Outside Japan>

Code No.	Category (Administration)	Indication	Stage	Origin	Development
S-2367 (Velneperit)	Neuropeptide Y Y5 receptor antagonist (Oral)	Obesity	USA: Phase II	In-house	In-house
S-349572/S-265744/S-247303	Integrase inhibitor (Oral)	HIV infection	USA, Europe: Phase IIb (the most advanced phase)	Shionogi & GlaxoSmithKline	Shionogi-GlaxoSmithKline Pharmaceuticals LLC (USA)
S-888711	Small molecule TPO mimetic (Oral)	Thrombocytopenia	USA, Europe: Phase II	In-house	In-house
S-555739	Prostaglandin D2 receptor antagonist (Oral)	Allergic disease	Europe: POM	In-house	In-house
S-297995	Peripheral opioid receptor antagonist (Oral)	Alleviation of opioid-induced adverse effect	USA: Phase IIa	In-house	In-house
S-234462	Neuropeptide Y Y5 receptor antagonist (Oral)	Obesity	USA: Phase I	In-house	In-house
S-707106	Insulin sensitizer (Oral)	Type 2 Diabetes	USA: Phase I	In-house	In-house
S-222611	Her2/EGFR dual inhibitor (Oral)	Malignant tumor	Europe: Phase Ib	In-house	In-house

<Out-Licensing Activity>

Code No. (Generic name)	Category (Administration)	Indication	Stage	Origin	Development
S-4661 (Doripenem hydrate)	Carbapenem antibiotic (Injection)	Bacterial infection	USA: Approval (October 2007) Complicated intra-abdominal infections, Complicated urinary tract infections including pyelonephritis NDA submission (June 2007) Hospital-acquired (nosocomial) pneumonia including ventilator-associated pneumonia EU: Approval	In-house	Peninsula (USA) ↓ Johnson & Johnson (USA)
S-0373	Non-peptide mimetic of TRH (Oral)	Spinocerebellar ataxia	Japan : Phase II	In-house	Kissei Pharmaceutical Co., Ltd.
S-3013 (Varespladib methyl)	Secretory PLA2(sPLA2) inhibitor (Oral)	Acute coronary syndromes Mixed dyslipidemia	USA, EU: Phase IIb	Shionogi & Eli Lilly and Company (USA)	Anthera (USA)

Since February, 2010

Change of phase	LY248686<In Japan> (Depression) : Approval → Launch
	S-021812<In Japan> : NDA submission (in preparation, pediatric) → NDA submission
	S-4661<In Japan> : Phase III (Addition of new dosage regimen) → NDA submission
	S-707106<Outside Japan> : Phase I (in preparation) → Phase I
	S-222611<Outside Japan> : Phase Ib (in preparation) → Phase Ib
Compound added to the list	S-474474<In Japan> : Phase III
	S-297995<Outside Japan> : Phase IIa
Compound erased	S-021812<In Japan> : Launched
	S-013420<In Japan> : Discontinued
	NS75B<In Japan> : Discontinued
	S-0139<Outside Japan and In Japan> : Discontinued

<Shionogi Pharma, Inc.> As of May 2010

Product (Generic name)	Category (Administration)	Indication	Stage	Origin	Development
Ulesfia (Benzyl alcohol)	Topical benzyl alcohol pediculocide (Topical lotion)	Head lice	Launch July 2009	Summers Laboratories, Inc	Summers Laboratories, Inc
Prenate DHA (Vitamins, minerals, DHA and metafolin)	Vitamins, minerals, metafolin (active form of folate) and omega-3 fatty acids (Oral)	Prenatal DHA vitamin	Launch April 2009 (NDA not required)	Shionogi Pharma, Inc.	Shionogi Pharma, Inc.
AdrenaClick (Epinephrine)	(Single-dose epinephrine auto-injector)	Anaphylaxis	Launch January 2010	Shionogi Pharma, Inc.	Shionogi Pharma, Inc.
Prenate Essential (Vitamin, minerals and metafolin)	Vitamins, minerals, metafolin (active form of folate), biotin and iodine (Oral)	Prenatal Vitamin	Launch April 2010 (NDA not required)	Shionogi Pharma, Inc.	Shionogi Pharma, Inc.
Glycopyrrolate (Glycopyrrolate oral solution)	Anticholinergic (Oral)	Chronic moderate-to-severe drooling in pediatric patients	USA: NDA filed September 2009	Shionogi Pharma, Inc.	Shionogi Pharma, Inc.
Clonidine HCL (Clonidine hydrochloride)	Centrally acting alpha adrenergic agonist (Oral)	Attention Deficit Hyperactivity Disorder (ADHD)	USA: sNDA filed October 2009	Addrenex Pharmaceuticals, Inc.	Shionogi Pharma, Inc. and Addrenex Pharmaceuticals, Inc.
Pravastatin/Fenofibrate (Pravastatin/fenofibrate combination)	Statin-HMG-CoA reductase inhibitors, fenofibrate lipid regulating agent (Oral)	Lowering non-HDL cholesterol and triglycerides	USA: NDA filed November 2009	Galephar, PR Inc / SMB Laboratories	Shionogi Pharma, Inc. and SMB Laboratories
Jenloga XR (Clonidine hydrochloride)	Centrally acting alpha adrenergic agonist (Oral)	Hypertension	USA: Phase III trial completed	Addrenex Pharmaceuticals, Inc	Shionogi Pharma, Inc. and Addrenex Pharmaceuticals, Inc.
PSD502 (Lidocaine/prilocaine)	Eutectic mixture of anesthetics (Metered-dose topical aerosol spray)	Premature Ejaculation (PE)	Europe: Phase III trial completed; USA: Second and final Phase III trial completed	Plethora Solutions Holdings PLC	Shionogi Pharma, Inc. and Plethora Solutions Holdings PLC
Ospemifene (Ospemifene)	Selective estrogen receptor modulator (SERM)	Post-menopausal Vaginal Atrophy	USA: Phase III trial completed	QuatRx Pharmaceuticals Company	QuatRx Pharmaceuticals Company and Shionogi Pharma, Inc.
ADX415	2 alpha specific adrenergic agonist (Oral)	Hypertension	USA: Phase II trial (in preparation)	Addrenex Pharmaceuticals, Inc.	Shionogi Pharma, Inc.

Since February, 2010

Compound added to the list	Prenate Essential (Vitamin, minerals and metafolin): Launched (NDA not required)
	Ospemifene (Ospemifene): Phase III trial completed